Lifordi Immunotherapeutics and other biotechnology companies are using antibodies to precisely target drugs in the body.
Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive ...
LONDON & SAN FRANCISCO-- (BUSINESS WIRE)--December 16, 2025-- ...
A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver ...
US FDA clears Mabwell’s IND application to initiate phase IIa study of novel anti-ST2 monoclonal antibody, 9MW1911 to treat moderate-to-severe COPD: Shanghai Monday, December 29 ...
The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...
A monkeypox vaccine or antibody therapy may have taken a step closer to reality, as AI reveals new drug target.
Dec 2 (Reuters) - The U.S. Food and Drug Administration on Tuesday issued new draft guidance on reducing the use of lab monkeys in preclinical toxicity studies for certain monoclonal antibodies. The ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global ...
Multiple myeloma is an incurable plasma cell malignancy despite major therapeutic advances. A recent review by Chinese ...
Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback